Bionano Genomics Announces American Society of Human Genetics Presentations Featuring Optical Genome Mapping for Genetic Disease and Cancer Research Applications
Talks featuring Bionano Genomics OGM solutions include research into how structural variation contributes to the cause of ALS; inverted genomic triplication structures; and a multi-site clinical validation study of constitutional postnatal SV, CNV and repeat array sizing, as well as findings of SVs in pediatric brain tumors, and epigenetics. Below is a list of customer presentations featuring OGM at this year’s ASHG conference.
|OGM Application Area||Presenter||Affiliation||Presentation Title|
|Inherited Genetic Disorders||Dr.
||Inverted genomic triplication structures: two breakpoint junctions, several possibilities|
||Macquarie Univ. Ctr. for
||Development of a discovery pipeline for structural variation contributing to the cause of amyotrophic lateral sclerosis|
||Optical Genome Mapping for Constitutional Postnatal SV, CNV, and Repeat Array Sizing: A Multisite Clinical Validation Study|
||Large-Scale, Multi-site, Postnatal Studies on Optical Genome Mapping (OGM)|
||Optical Genome Mapping Improves the Clinically Relevant Structural Variant Detection in MDS|
||Children's Hospital Los Angeles||Utilization of Optical Genome Mapping in Detection and Characterization of Rare Genetic Markers in Pediatric Leukemias|
|Solid Tumor Analysis||Dr.
||Optical genome mapping reveals novel structural variants in pediatric brain tumors|
||Utilization of Dual-Label Optical Genome Mapping for genetic/epigenetic diagnosis|
“We are delighted to see the broad range of presentations on OGM at ASHG this year,” stated
For more details and to register for this online event please go to: https://www.ashg.org/meetings/2021meeting/
Bionano is a genome analysis company providing tools and services based on its Saphyr® system to scientists and clinicians conducting genetic research and patient testing; it also provides diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the posters and presentations regarding OGM to be presented at the ASHG conference. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the accuracy of customer posters and presentations to be presented; observations from studies covered by the posters and presentations may not be replicated; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
+1 (858) 888-7610
+1 (858) 366-3243
+1 (503) 799-7520
Source: Bionano Genomics